MSD Sponsored Satellite Symposium at UKIBCS Conference 2024

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

The MSD Sponsored Symposium at UK Interdisciplinary Breast Cancer Symposium (UKIBCS) took place on the 23rd of January 2024 at the ICC Birmingham. The Symposium was led by Professor Peter Schmid, and included a panel discussion with Dr Melissa Phillips and Dr Duncan Wheatley.

The Symposium included a 5-year data update on the KEYNOTE-522 study for the treatment of early stage triple negative breast cancer (TNBC) patients at high risk of recurrence. This was followed by a panel discussion and Q&A session focusing on hot topics in early TNBC.

This symposium was a promotional meeting fully organised and funded by MSD and MSD products were discussed at the meeting.

Read more about the 60-month exploratory analysis for KEYNOTE-522 in the below report.

UKIBCS Symposium report

Click on the resource to download.

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer, at high-risk of recurrence.1

Please refer to Summary of Product Characteristics for full list of AEs and management.

More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)


  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website